Team,
Did you know that, starting in his first term in Congress, Peter has consistently advocated to allow Medicare to negotiate lower prescription drug prices on behalf of its enrollees?
Now, it’s the law of the land.
Under the Inflation Reduction Act, which President Biden signed into law yesterday, Medicare will be allowed to negotiate drug prices for the very first time in history. This provision is expected to save Americans an estimated $265 billion over the next decade, and will provide much needed relief for families and seniors who have been struggling with sky-high costs at the pharmacy counter.
Getting this done is a big deal, and a big win for Americans—yet Mitch McConnell and national Republicans (including our opponent) are all against it. It’s a reminder of what’s at stake in this election: we can have a Senate that fights to help everyday Americans, or one that fights for the powerful interest groups. It’s essential we win this election for Peter and keep our progressive vision alive.
If you’ve saved payment info with ActBlue Express, your donation will process automatically:
|
|
|
|
|
|
All across the country, individuals and families alike are feeling the pinch of rising costs. The Inflation Reduction Act will take that issue on directly by lowering costs tied to health care and prescription drugs—all while reducing the federal deficit and building a fairer tax code that ensures the largest corporations pay their fair share. Talk about much-needed relief!
This new landmark law is a signal to every large corporation that has repeatedly and recklessly put profits over people: We’re fighting back. But unfortunately, Peter and his Democratic colleagues passed the IRA without a single vote from Republicans. With the Senate split 50/50, the only chance we have to pass more legislation like this is electing more progressive Democrats. Thankfully, we’ve got one heck of a candidate in Peter Welch.
Thanks so much!
Team Welch
|
|
|
|||
PAID FOR BY WELCH FOR VERMONT
Welch for Vermont
P.O Box 909
Richmond, VT 05477
This email was sent to [email protected]. If you believe you received this email in error or wish to no longer receive emails from us, please unsubscribe here.